Benzinga | Mar 16, 2021 07:16AM EDT

Enzo Therapeutics Awarded U.S. Patent 10,945,971 'Sphingosine kinase type 1 inhibitors and uses thereof'

Provided are inhibitors of sphingosine kinase Type I that are useful in a number of applications, indications and diseases, as well as for monitoring pharmacokinetics and patient management. These compounds are applicable to treating ischemic diseases such as myocardial infarction and stroke.